VA
WST icon

Vident Advisory’s West Pharmaceutical WST Stock Holding History

Vident Advisory’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.3M Buy
45,454
+1,850
+4% +$566K 0.12% 161
2026
Q1 		$10.9M Sell
43,604
-10,091
-19% -$2.51M 0.09% 192
2025
Q4 		$14.8M Sell
53,695
-363
-0.7% -$99.3K 0.13% 137
2025
Q3 		$14.2M Buy
54,058
+1,991
+4% +$484K 0.14% 142
2025
Q2 		$11.4M Buy
52,067
+49,039
+1,620% +$10.5M 0.13% 148
2025
Q1 		$678K Buy
3,028
+643
+27% +$177K 0.01% 878
2024
Q4 		$781K Buy
2,385
+484
+25% +$152K 0.01% 746
2024
Q3 		$571K Sell
1,901
-9,881
-84% -$3.03M 0.01% 858
2024
Q2 		$3.88M Buy
11,782
+2,271
+24% +$803K 0.11% 189
2024
Q1 		$3.76M Buy
9,511
+7,835
+467% +$2.9M 0.08% 252
2023
Q4 		$590K Buy
1,676
+12
+0.7% +$4.25K 0.01% 716
2023
Q3 		$624K Buy
+1,664
New +$644K 0.02% 640

Other funds holding WST

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Vident Advisory's WST Position: Q2 2026 in Review

Vident Advisory increased its West Pharmaceutical (WST) stake by 4.2% in Q2 2026, buying an estimated $566K and bringing the position to 45,454 shares worth $16.3M. The position accounts for 0.12% of the portfolio, ranked #161.

Vident Advisory first reported a position in WST in Q3 2023 and has held it in 12 quarters since. 834 funds tracked by Wall St. Rank hold WST as of Q2 2026.

  • Vident Advisory held 45,454 shares of West Pharmaceutical worth $16.3M as of Q2 2026.
  • Vident Advisory bought 1,850 West Pharmaceutical shares in Q2 2026, an estimated $566K.
  • West Pharmaceutical made up 0.12% of Vident Advisory's portfolio in Q2 2026, its #161 holding.
  • Vident Advisory first reported a position in West Pharmaceutical in Q3 2023 and has held it in 12 quarters since.
  • 834 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2026.

Based on Vident Advisory's 13F filing for Q2 2026, filed 12 Aug 2026.